MX2017006800A - Formulaciones de complejo de lantanido. - Google Patents

Formulaciones de complejo de lantanido.

Info

Publication number
MX2017006800A
MX2017006800A MX2017006800A MX2017006800A MX2017006800A MX 2017006800 A MX2017006800 A MX 2017006800A MX 2017006800 A MX2017006800 A MX 2017006800A MX 2017006800 A MX2017006800 A MX 2017006800A MX 2017006800 A MX2017006800 A MX 2017006800A
Authority
MX
Mexico
Prior art keywords
lanthanide
chelator
complex formulations
lanthanide complex
ions
Prior art date
Application number
MX2017006800A
Other languages
English (en)
Inventor
Richard Meijer Andreas
Jacob THANING Mikkel
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of MX2017006800A publication Critical patent/MX2017006800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método de remoción de impurezas de iones metálicos, tal como calcio, a partir de complejos de metal de lantánido de quelantes macrocíclicos. El método usa una resina depuradora para remover iones metálicos, desplazados de quelante, mediante un exceso de iones de lantánido. También se proporciona un método de preparación de agentes de contraste de MRI, a partir del complejo de metal de lantánido purificado, mediante la adición de un exceso definido de quelante. (ver Grafica).
MX2017006800A 2014-11-28 2015-11-27 Formulaciones de complejo de lantanido. MX2017006800A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1421162.7A GB201421162D0 (en) 2014-11-28 2014-11-28 Lanthanide complex formulations
PCT/EP2015/077970 WO2016083605A1 (en) 2014-11-28 2015-11-27 Lanthanide complex formulations

Publications (1)

Publication Number Publication Date
MX2017006800A true MX2017006800A (es) 2017-09-08

Family

ID=52349617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006800A MX2017006800A (es) 2014-11-28 2015-11-27 Formulaciones de complejo de lantanido.

Country Status (12)

Country Link
US (3) US10576169B2 (es)
EP (1) EP3224250A1 (es)
JP (1) JP6846347B2 (es)
KR (2) KR20170092546A (es)
CN (1) CN107001293B (es)
AU (1) AU2015352426B2 (es)
BR (1) BR112017010889B1 (es)
CA (1) CA2967877A1 (es)
GB (1) GB201421162D0 (es)
MX (1) MX2017006800A (es)
RU (1) RU2707070C2 (es)
WO (1) WO2016083605A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421162D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
CN110114093A (zh) * 2016-12-29 2019-08-09 创意有限责任公司 无溶剂钆造影剂
US20190269805A1 (en) 2016-12-29 2019-09-05 Inventure, LLC Solvent-free gadolinium contrast agents
US11654424B1 (en) * 2019-06-10 2023-05-23 Triad National Security, Llc Method embodiments for making lanthanide metal complexes from lanthanide metal oxides and separating the same from heavy lanthanide metal oxides, actinide oxides, and non-lanthanide rare earth element oxides
GB201919073D0 (en) * 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
CN113527222B (zh) * 2020-04-21 2023-06-13 威智医药股份有限公司 一种钆特酸葡甲胺的制备方法
CN113801071B (zh) * 2021-09-14 2023-04-07 安徽普利药业有限公司 一种钆特酸葡甲胺的精制方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028234A (en) 1974-06-06 1977-06-07 Aerojet-General Corporation Buffering agents
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
WO1989012631A1 (en) * 1988-06-24 1989-12-28 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
IT1269839B (it) * 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
US5665239A (en) 1996-01-16 1997-09-09 Culligan International Company Processes for deionization and demineralization of fluids
IT1292128B1 (it) 1997-06-11 1999-01-25 Bracco Spa Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici
FR2772025B1 (fr) 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
US20040167330A1 (en) 2001-07-17 2004-08-26 Ivan Lukes Novel chelating agents and conjugates thereof, their synthesis and use as diagnois and therapeutic agents
WO2008144728A1 (en) * 2007-05-21 2008-11-27 Bracco Imaging S.P.A. Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2945448B1 (fr) 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
EP2338874A1 (en) 2009-12-16 2011-06-29 Bracco Imaging S.p.A Process for the preparation of chelated compounds
WO2014114664A1 (en) 2013-01-28 2014-07-31 Agfa Healthcare Process for producing 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid and complexes thereof
EP2786768A1 (en) 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
GB201421162D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations

Also Published As

Publication number Publication date
EP3224250A1 (en) 2017-10-04
RU2017116220A (ru) 2018-12-28
KR20170092546A (ko) 2017-08-11
JP6846347B2 (ja) 2021-03-24
KR20230125860A (ko) 2023-08-29
US10576169B2 (en) 2020-03-03
US11400172B2 (en) 2022-08-02
AU2015352426A1 (en) 2017-05-25
CN107001293A (zh) 2017-08-01
KR102608019B1 (ko) 2023-11-30
US20220354971A1 (en) 2022-11-10
WO2016083605A1 (en) 2016-06-02
US20200155712A1 (en) 2020-05-21
BR112017010889B1 (pt) 2022-02-22
CA2967877A1 (en) 2016-06-02
AU2015352426B2 (en) 2020-03-05
CN107001293B (zh) 2023-09-19
BR112017010889A2 (pt) 2018-02-14
GB201421162D0 (en) 2015-01-14
RU2017116220A3 (es) 2019-02-25
JP2017535553A (ja) 2017-11-30
US20170258945A1 (en) 2017-09-14
RU2707070C2 (ru) 2019-11-22

Similar Documents

Publication Publication Date Title
MX2017006800A (es) Formulaciones de complejo de lantanido.
MX2018012016A (es) Compuestos biciclicos.
PH12017502024A1 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
MX2015008927A (es) Proceso para la preparacion de oxiranos y triazoles sustituidos.
MX2018003280A (es) Proceso de compuesto antifungico.
MX2017006799A (es) Formulaciones de complejo de metal.
PH12014502413A1 (en) Cyclic bridgehead ether dgat1 inhibitors
MX2015011193A (es) Compuestos antivirales.
MX362879B (es) Usos novedosos.
PH12018550165A1 (en) An improved process for the preparation of butorphanol tartrate
SG10201900541QA (en) Derivatives of xanthone compounds
MX337785B (es) Procedimiento de preparacion de polioles de polieter.
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
MX2015011198A (es) Compuestos antivirales.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
IN2013MU01113A (es)
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
EA201591449A1 (ru) Способы получения противораковых композиций
MX2015010892A (es) Compuestos antivirales.
IN2013MU00916A (es)
MX369008B (es) Un proceso mejorado para la preparación de exametazima.
SG10201803880TA (en) Stable compositions of neuroactive peptides
MX2016002198A (es) Proceso para la preparación de un compuesto.